DERM.AI has been designed to diagnose skin cancer to support the dermatology capacity crisis, and the building backlog of 2ww skin cancer referrals.
In primary care, DERM.AI enables GPs to provide a specialist level assessment within a standard consultation, with an immediate outcome. Allowing the GP to treat or discharge the patient, or refer for 2ww if malignancy is detected. Using DERM.AI within primary care should see a reduction of referrals to secondary care of up to 60%.
Acute trusts can use DERM.AI to triage patients on their 2ww pathway, to ensure consultant dermatologists only see patients with malignant lesions. Our latest NHS deployment at University Hospital Birmingham has helped to discharge around 40% of patients without the need for a dermatology appointment at all.
The detailed report generated from DERM.AI includes the patient medical history, lesion history and biopsy eligibility questions as well as the dermoscopic and macroscopic images. Attached to e-RS the dermatologists can provide remote teledermatology for lesions referred by DERM.AI in place of a face-to-face appointment.
DERM.AI is scalable by leveraging HCAs, nurses or medical photographers in community diagnostic clinics or RDC’s, to support the recovery of dermatology capacity and the growing cancer backlog.
Alternatively the Skin Analytics platform can be used to design new innovative pathways, as being built with Mid South Essex CCG, allowing for referral straight to biopsy, further reducing the requirement for face-to-face dermatology appointments and quicker cancer diagnosis.
The Skin Analytics platform has been designed with clinical utility in mind, using a secure IG compliant cloud based software, for the easy transfer of images to the case. This ensures no data is left on the device, and there’s no need for wires, manual upload of photos.
Skin Analytics provides all the hardware, software and training to deliver an AI teledermatology solution that can be deployed within two weeks.
Skin Analytics research
Skin Analytics is supported by the NHS Innovation Accelerator in its capacity as a support tool within the cancer pathway, not as a replacement for diagnosis by a healthcare professional. For the most current information on Skin Analytics’ regulatory status, please contact Neil Daly at firstname.lastname@example.org.